CLINICAL & PIPELINE·Drug Approval
Merck's SEGLUROMET: Strategic Implications of a Type 4 New Combination Approval and Ongoing Labeling Updates for Diabetes Management
Merck Sharp & Dohme LLC's SEGLUROMET, a fixed-dose combination of Ertugliflozin and Metformin Hydrochloride, received its original Type 4 New Combination approval from the FDA on December 19, 2017. This strategic approval, coupled with continuous labeling updates, including a forthcoming one in December 2024, underscores Merck's commitment to the Type 2 Diabetes market and presents critical considerations for pharmaceutical supply chain and regulatory affairs.
90-Day Activity